Selective COX-2 inhibitors: where do we go from here?

Lancet. 2008 Nov 15;372(9651):1712-3. doi: 10.1016/S0140-6736(08)61491-9. Epub 2008 Oct 14.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cyclooxygenase 2 Inhibitors / adverse effects*
  • Humans
  • Lactones / adverse effects*
  • Randomized Controlled Trials as Topic
  • Sulfones / adverse effects*
  • Thrombosis / chemically induced*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib